Faye L Abbesse

Researchers are evaluating the effects of 15 sessions of transcranial direct current stimulation tDCS on reducing suicidal thoughts in adults with treatment-resistant depression. This pilot study involves participants diagnosed with recurrent or isolated depressive episodes who have stable antidepressant treatment and significant suicidal ideation. The goal is to see if daily 30-minute sessions of tDCS at 2 mA intensity can lower suicidal ideation scores. Participants will receive one tDCS session per day for 15 days, each lasting 30 minutes with a current of 2 mA. After completing these sessions, they will attend three follow-up visits on days 19, 49, and 79 to monitor changes. The study is conducted without blinding and focuses on the active tDCS intervention. During the study, participants will undergo assessments of suicidal ideation using the Scale for Suicide Ideation and the implicit association test at baseline and follow-up visits. Depression severity will be measured with the Montgomery and Asberg Depression Rating Scale MADRS, and quality of life will be evaluated with the SF36 survey. These measures will help researchers understand changes over time and the safety of the treatment. Participants are involved for approximately 79 days including follow-ups.

The Dataids cohort is a large, ongoing observational study following over 30,000 HIV-infected patients receiving care at more than 15 HIV centers across France. The study aims to monitor clinical practice, changes in the course of HIV infection and related co-infections or co-morbidities, and assess factors influencing the clinical, immunological, and virological outcomes of HIV. It also evaluates the effectiveness of antiretroviral therapy ART and outcomes related to hepatitis C virus HCV treatment. Patients enrolled in the cohort are followed during routine outpatient visits, regardless of their CD4 cell count, HIV viral load, or ART status. Data collected annually include demographic information, immunological and virological measures, serological tests for hepatitis B, hepatitis C, and syphilis, as well as laboratory, therapeutic, and clinical data. This long-term study has been enrolling patients since 2010 and continues to collect data prospectively. Participants provide data through their scheduled clinic visits, and researchers track outcomes such as the proportion of patients with undetectable HIV viral load, ART usage patterns, HCV treatment uptake and success, CD4 cell counts, and incidence of HIV-related events. The main outcome measured is the proportion of treated patients with HIV plasma viral load below 50 copiesmL, averaged over six months. The study extends through 2030, with ongoing annual monitoring and data collection as part of routine care.